Oncolytics’ Pelareorep Earns Fast Track after 33% Response in KRAS-Mutant Colorectal Cancer
Oncolytics Biotech's pelareorep gained FDA Fast Track status for second-line KRAS-mutant microsatellite-stable metastatic colorectal cancer after delivering a 33% response rate and 27-month median survival versus 11.2 months with chemotherapy and Avastin. The designation accelerates FDA review in $3–5 billion second-line market and highlights 16.6-month progression-free survival versus 5.7 months.
1. Fast Track Designation
The FDA granted Fast Track status to pelareorep for second-line treatment of KRAS-mutant microsatellite-stable metastatic colorectal cancer. This designation can enable more frequent regulatory interactions and a potentially expedited approval pathway for the therapy.
2. Efficacy Results in KRAS-Mutant CRC
In a trial combining pelareorep with standard chemotherapy and Avastin, patients achieved a 33% objective response rate versus roughly 10% with chemotherapy and Avastin alone. Median overall survival reached 27 months compared to 11.2 months, and progression-free survival extended to 16.6 months versus 5.7 months.
3. Upcoming Controlled Study and Market Outlook
Oncolytics plans a randomized controlled trial comparing standard care with and without pelareorep, with the first site activation in March and interim data expected by year-end 2026. The global second-line KRAS-mutant MSS colorectal cancer market is estimated at $3–5 billion annually.
4. Additional Programs and Leadership Hires
Pelareorep has also shown a 29% response rate in third-line anal cancer and a 30% response in second-line patients. To support these programs, Oncolytics recently appointed John McAdory as EVP of Strategy and Operations and Yujun Wu as VP, Head of Biostatistics.